<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916015</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0062</org_study_id>
    <nct_id>NCT04916015</nct_id>
  </id_info>
  <brief_title>Histomolecular Profiles of Gliomas in Children and Adolescent/Young Adults</brief_title>
  <acronym>BioMol GLIOMA</acronym>
  <official_title>Comparative Study of the Histomolecular, Radiological and Prognostic Profiles Between Brain Gliomas of Children (0-14 Years) and Adolescents/Young Adults (15-25 Years) Treated in the Amiens University Hospital Between 2008 and 2020</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last decades, many advances have been made in the field of genetic abnormalities of&#xD;
      glial and glioneuronal brain tumors. In the 2016 World Health organization (WHO)&#xD;
      Classification of Tumors of the Central Nervous System, the concept of &quot;integrated&quot; diagnosis&#xD;
      emerged: histological and genetic/molecular features now define many entities. Since 2016,&#xD;
      six updates have been published by the c-IMPACT-NOW (the Consortium to Inform Molecular and&#xD;
      Practical Approaches to CNS Tumor Taxonomy- Not Official WHO) to develop and clarify the&#xD;
      &quot;integrated&quot; diagnosis. In the future WHO 2021 Classification of Tumors of the Central&#xD;
      Nervous System, &quot;integrated&quot; diagnoses will take up even more importance. Even if they can&#xD;
      have similar histological features, gliomas of children are very different from the &quot;adult&quot;&#xD;
      gliomas in the molecular mechanism of oncogenesis. The histomolecular features of&#xD;
      adolescents/young adults (AYAs) can have similarities with &quot;pediatric-type&quot; or &quot;adult-type&quot;&#xD;
      gliomas, but few studies have focused specifically on the histomolecular profiles of gliomas&#xD;
      in AYAs.&#xD;
&#xD;
      The investigators would like to study the cohort of patients treated for a glial and&#xD;
      glioneuronal tumor diagnosed under the age of 25 in the Amiens University Hospital between&#xD;
      2008 and 2020. The investigators would like to compare the histomolecular profiles of gliomas&#xD;
      in children (0-14 years) and AYAs (15-25 years).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histogical glioma differences between child group(0-14 years) and AYA group (15-25 years)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular glioma differences between child group(0-14 years) and AYA group (15-25 years)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of glioma MRI profile between child group(0-14 years) and AYA group (15-25 years)</measure>
    <time_frame>one year</time_frame>
    <description>MRI profiles are EPI T2* MRI profiles</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Histological</condition>
  <condition>Molecular Sequence Variation</condition>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>children (0-14 years)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>AYAs (15-25 years)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated for a glial and glioneuronal tumor diagnosed under the age of 25 in the&#xD;
        Amiens University Hospital between 2008 and 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient&#xD;
&#xD;
          -  Patient treated in the Amiens University Hospital&#xD;
&#xD;
          -  Patient treated for a glial or glioneuronal brain tumor according to the 2016 WHO&#xD;
             Classification of Tumors of the Central Nervous System (&quot;diffuse oligodendroglia or&#xD;
             astrocytoma tumour,&quot; &quot;another astrocytic tumor,&quot; &quot;another glioma&quot; or a &quot;mixed neuronal&#xD;
             or glioneuronal tumour&quot;).&#xD;
&#xD;
          -  Diagnosis histologically confirmed or formally established by radiologist.&#xD;
&#xD;
          -  Diagnosis established between January 1, 2008 and December 31, 2020.&#xD;
&#xD;
          -  No patient opposition (from adult patient, or from the holder of parental authority of&#xD;
             the minor patient).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncertain diagnosis&#xD;
&#xD;
          -  Patient opposition (from adult patient, or from the holder of parental authority of&#xD;
             the minor patient).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine Gourmel, MD</last_name>
    <phone>03.22.08.76.48.</phone>
    <email>gourmel.antoine@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Gourmel, MD</last_name>
      <phone>03.22.08.76.48.</phone>
      <email>gourmel.antoine@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histological</keyword>
  <keyword>Molecular</keyword>
  <keyword>Glioma</keyword>
  <keyword>adolescents/young adults</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

